Your browser is no longer supported. Please, upgrade your browser.
Evaxion Biotech A/S
Index- P/E- EPS (ttm)-0.79 Insider Own- Shs Outstand17.44M Perf Week14.69%
Market Cap106.21M Forward P/E- EPS next Y-1.54 Insider Trans- Shs Float9.35M Perf Month-20.08%
Income-15.00M PEG- EPS next Q-0.30 Inst Own- Short Float0.07% Perf Quarter-
Sales- P/S- EPS this Y-102.30% Inst Trans- Short Ratio0.05 Perf Half Y-
Book/sh- P/B- EPS next Y-29.40% ROA- Target Price- Perf Year-
Cash/sh0.45 P/C13.44 EPS next 5Y- ROE- 52W Range5.16 - 10.34 Perf YTD-38.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.10% Beta-
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low24.15% ATR0.66
Employees35 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)46.84 Volatility10.66% 10.71%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.02 Prev Close6.09
ShortableYes LT Debt/Eq0.00 EarningsApr 06 BMO Payout- Avg Volume146.20K Price6.40
Recom1.00 SMA20-0.88% SMA50-13.00% SMA200-13.00% Volume149,478 Change5.09%
Apr-06-21 07:30AM  
Mar-30-21 07:30AM  
Mar-16-21 07:30AM  
Mar-05-21 03:30PM  
Feb-16-21 07:30AM  
Feb-10-21 07:30AM  
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.